Literature DB >> 33128717

Use of 18F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography in Assessing Response to Neoadjuvant Chemoradiation and Its Impact on Survival in Esophageal Squamous Cell Carcinoma.

Sayed Assif Iqbal1, Shaifali Goel1, Abhishek Aggarwal1, Nikhil Gupta1, Manoj Gupta2, Garima Durga3, Vineet Talwar4, Shivendra Singh5.   

Abstract

BACKGROUND: To determine the accuracy of 18F-Fluorodeoxyglucose positron emission tomography computed tomography (FDG-PET CT) in predicting response to neoadjuvant chemoradiation (NACRT) in esophageal squamous cell cancer (SCC) and impact of such response on survival.
METHODS: Retrospective analysis of patients with esophageal SCC (cT2-4N0-N+M0) who underwent PET CT before and 6 weeks after NACRT followed by surgery was carried out in this study. Metabolic response was assessed by change in standardized uptake value (ΔSUVmax) after NACRT and the pathological response was graded. A receiver operating characteristic curve (ROC) was used to identify the optimal cut off value of SUVmax to predict histopathological response. The impact of metabolic response and pathological response on survival was determined.
RESULTS: Of the 73 patients analyzed, 27 had complete metabolic response, while 24 had pathological complete response (PCR). However, only 14 of the 27 complete metabolic responders actually had PCR. At 67% ΔSUVmax, the optimum balance between sensitivity (70.83%) and specificity (69.23%) was achieved and the correlation between metabolic response and pathological complete response achieved statistical significance (p = 0.0009). However, ΔSUVmax of 67% was found to have no significant association with survival (p = 0.51). PCR was the only significant determinant of improved survival (p = 0.04).
CONCLUSION: PCR which is a significant determinant of survival is not ideally predicted by ΔSUVmax on PET CT.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Complete pathological response; Esophageal carcinoma; Neoadjuvant chemoradiotherapy; PET scan

Mesh:

Substances:

Year:  2020        PMID: 33128717     DOI: 10.1007/s12029-020-00543-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  1 in total

1.  [S-methyl-11C]-L-methionine positron emission tomography/computed tomography imaging parameters to evaluate early response for esophageal cancer with neoadjuvant carbon ion radiotherapy.

Authors:  Kazuo Narushima; Ryuichi Nishii; Shinichi Okazumi; Hideaki Shimada; Yasunori Akutsu; Takamasa Maeda; Shigeo Yasuda; Shigeru Yamada; Kiyohiko Shuto; Kentaro Tamura; Kana Yamazaki; Makoto Shinoto; Hitoshi Ishikawa; Mikito Mori; Hisahiro Matsubara
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.